VRTX

Vertex Pharmaceuticals Incorporated

Healthcare
499.74 down -9.01 -1.77% Pre-Market
2026-10-16 • USD

Key Metrics

Market Cap 126.66B
EV 120.79B
Shares Out 253.46M
Revenue (ttm) 12.59B
Net Income 4.41B
Beta —
P/E —
Forward P/E —
EPS (ttm) $17.17
P/S 10.07
P/B 6.26
P/FCF 33.40
P/C 29.53
EV/Sales 9.60
EV/EBITDA 24.16
ROA 16.85%
ROE 23.45%
ROIC 17.95%
Gross Margin —
Oper. Margin 37.95%
Profit Margin 35.0%
Debt/Eq 0.10
LT Debt/Cap —
Quick Ratio 2.54
Current Ratio 3.19
Book/sh 79.81
Cash/sh 24.22
Div Yield —
Div TTM —
Payout Ratio —
SMA20 -2.04%
SMA50 -4.36%
SMA200 5.01%
Volume 1,408,420
Avg Volume 1.38M
Rel Volume 1.02
Perf Week -1.43%
Perf Month -1.69%
Perf Quarter 2.90%
Perf Half Y 13.27%
Perf YTD 10.23%
Perf Year 19.90%
Perf 3Y 36.99%
Perf 5Y 169.53%

Factor Lens

Seasonal Performance

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Vertex Pharmaceuticals is a global biotechnology company focused on discovering, developing, and commercializing innovative medicines by combining transformative advances in human…

Name
Vertex Pharmaceuticals Incorporated
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Reshma Kewalramani · Chief Executive Officer and President
Employees
—
IPO Date
2020-04-24
Phone
(617) 341-6100
Address
50 Northern Avenue, Boston, MA 02210
Website
—

Key Executives

Name Title FY Pay
Nia Tatsis Executive Vice President —
Amit Sachdev Executive Vice President, Chief Commercial Officer —
Carmen Bozic Chief Medical Officer —
Jeffrey M. Leiden Executive Chairman —
Reshma Kewalramani Chief Executive Officer and President —

Latest News